The 16 million U.S. cancer survivors are finding their voice, and –slowly– they’re beginning to influence both clinical practice and the allocation of research funds. For instance, we’re already seeing research and education devoted to the mounting co-morbidities as cancer survivors live longer. The implications for biopharma are profound. Find out how this shift is reshaping cancer research and clinical practice–and the impact it will have on the allocation of research dollars. In the context, discover how the looming physician shortage has implications for the emergence and increasing use of complex immunotherapy drugs, whose late-treatment effects on patients remain largely unknown.